View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 1, 2020updated 12 Jul 2022 11:39am

ACRO releases report on risk-based framework approach within decentralised trials

Activities of clinical studies have been traditionally cantered around trial sites where participants travel for enrolment.

Activities of clinical studies have been traditionally centred around trial sites where participants travel for enrolment.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This approach is either time-consuming or can place a cost burden on patients, creating an inconvenience. This further leads to a limit in enrolment speed and trial completion.

In order to ‘transcend’ these limitations, clinical researchers are in the process of exploring new ways to identify emerging mobile technologies, as well as increased connectivity within decentralised clinical trials.

Realising the importance of mitigating uncertainty around creating and implementing decentralised clinical trials (DCTs), the Association of Clinical Research Organizations (ACRO) and its member company Decentralized Clinical Trials Working Party have released tools that outline the best practices of the industry.

ACRO Global Regulatory Policy senior vice-president said Karen Noonan said: “We are very pleased to issue ACRO’s white paper ‘Decentralizing Clinical Trials: A New Quality-by-Design, Risk-Based Framework’.

“The paper and the accompanying toolkit provide a set of operational best practices for the implementation of decentralised clinical trials that will be helpful to sponsors and research organisations as we increasingly see technology-enabled trials that reduce burdens on patients and research sites alike.”

The toolkit comprises a ‘Quality-by-Design Manual’ for bringing the trial to the patient and a DCT risk assessment considerations spreadsheet to complement organisations’ current risk assessment tools.

ACRO Board Chair Alistair Macdonald said: “Decentralised trials have provided the pathway, where appropriate, to continue to service patients and to keep trials up and running despite site access limitations during the pandemic.

“ACRO members were able to quickly adapt by using innovative DCT tools to collect patient data during this time, including remote monitoring techniques, telemedicine and the use of remote and wearable devices”.

In May last year, ACRO in the US called for the adoption of risk-based monitoring (RBM) of clinical trials to ensure safer, efficient and quality studies.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena